Retrospective study of clozapine use in Ile-de-France;Étude rétrospective sur l'utilisation de la clozapine en Île-de-France

Encephale

Volumn 32, Issue 5 I, 2006, Pages 688-696

  Hiltgen, S ^a   Mantelet, S ^b   Pinabel, F ^c   Enjaume, F ^d  

^a HÔPITAL MAISON BLANCHE   (France)

^b Psychiatre   (France)

^c Psychiatre   (France)

^d AVICENNE HOSPITAL   (France)

Author keywords

Clozapine; Granulopenia; Resistant schizophrenia; Side effects

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

ADULT; AGRANULOCYTOSIS; ARTICLE; AUDITORY HALLUCINATION; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; EPILEPSY; FEMALE; FOLLOW UP; FRANCE; HOSPITALIZATION; HUMAN; LIFESPAN; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; MENTAL DISEASE; MENTAL PATIENT; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PATIENT MONITORING; PRESCRIPTION; PSYCHIATRIST; QUESTIONNAIRE; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; SUICIDE ATTEMPT; SYMPTOMATOLOGY; THERAPY EFFECT; TREATMENT DURATION; TREATMENT INDICATION; CHEMICALLY INDUCED DISORDER; CLINICAL PRACTICE; DRUG COMBINATION; DRUG RESISTANCE; MIDDLE AGED; PSYCHOLOGY; TREATMENT OUTCOME;

ADULT; AGRANULOCYTOSIS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 33750962860     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0013-7006(06)76220-0     Document Type: Article

References (20)

1. AZORIN JM. Clozapine : quelques aspects actuels. Inform Psychiatr 1995 ; 9 : 932-41.
2. BENTE D, ENGELMEIER MP, HEINRICH K et al. Klinische untersuchurger mit einem neuroleptischwirtsamen dibenzothiazepinderivat. Arzneimittelforschung Drug Res 1966 ; 16 : 314-6.
3. CAROFF SN, MANN SC, CAMPBELL EC et al. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 2002 ; 63 (Suppl 4) : 12-9.
4. CASADEBAIG F, PHILIPPE A, GUILLAUD-BATAILLE et al. Schizophrenic patients : physical health and access to somatic care. Eur Psychiatry 1997 ; 12 (6) : 289-93.
5. CHALASANI L, KANT R, CHENGAPPA KN. Clozapine impact on clinical outcomes and aggression in severely ill adolescents with childhood-onset schizophrenia. Can J Psychiatry 2001 ; 46 (10) : 965-8.
6. GAUSSARES C. Indications for clozapine. Encéphale 1992 ; 18 (Spec no 3) : 433-6.
7. GREEN AI, TOHEN M, PATEL JK et al. Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry 2000 ; 157 (6) : 982-6.
8. GROSS H, LANGNER E. Effect profile of a chemically new broad spectrum neuroleptic of the dibenzo-diazepine group. Wien Med Wochenschr 1966 ; 116 (40) : 814-6.
9. KANE J, HONIGFELD G, SINGER J et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988 ; 45 (9) : 789-96.
10. KANE JM. Clozapine in the treatment of schizophrenia. Encéphale 1991 ; 17 (Spec no 2) : 159-63.
11. KAPUR S, SEEMAN P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatr Neurosci 2000 ; 25 (2) : 161-6.
12. KAPUR S, SEEMAN P. Does fast dissociation from the dopamine D (2) receptor explain the action of atypical antipsychotics : a new hypothesis. Am J Psychiatry 2001 ; 158 (3) : 360-9.
13. KRONIG MH, MUNNE RA, SZYMANSKI S et al. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 1995 ; 152 (2) : 179-82.
14. LAMARQUE V. Hematologic effects of clozapine : a review of the international experience. Encéphale 1996 ; 22 (Spec no 6) : 35-6.
15. LIEBERMAN JA, KANE JM, SAFFERMAN AZ et al. Predictors of response to clozapine. J Clin Psychiatry 1994 ; 55 (Suppl B) : 126-8.
16. MELTZER HY, ALPHS L, GREEN AI et al. Clozapine treatment for suicidality in schizophrenia : International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003 ; 60 (1) : 82-91.
17. NABER D, LEPPIG M, GROHMANN R et al. Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia - a retrospective study of 387 patients. Psychopharmacology (Berl) 1989 ; 99 (Suppl) : S73-6.
18. NOVARTIS. Leponex (clozapine) en pratique. Rueil-Malmaison : Novartis Pharma SA, 2001.
19. PERE JJ, CHAUMET-RIFFAUD PH, BOURDEIX J et al. La clozapine (Leponex) en France. Inform Psychiatr 1993 ; 4 : 389-97.
20. STAHL SM. «Hit-and-Run» actions at dopamine receptors, part 2 : Illustrating fast dissociation from dopamine receptors that typifies atypical antipsychotics. J Clin Psychiatry 2001 ; 62 (10) : 747-8.